Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

We recently published a list of 10 Stocks Got Wiped Out. Are You Holding Any? In this article, we are going to take a look at ...

According to the company, eligible customers are now able to access six months of "prescription-only" Wegovy at a new and affordable price for $549 per month.

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Stay on our website for longer than five minutes and you’re bound to find references to Schaeffer’s Volatility Scorecard (SVS ...

Our writer takes a look at three red-hot growth stocks that have more than doubled this year to see if any of them interest ...

Thermo Fisher has unleashed its next-generation TruNarc Delta and Tau Handheld Narcotics Analyzers to help law enforcement ...

Large-cap stocks were the worst performers last week, with declines up to 23%. Reasons include revenue misses, FDA bans, and Uber's stake monetization.

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Hims & Hers Health (HIMS) has received mixed ratings from Top Wall Street analysts, with Morgan Stanley (MS) maintaining a Hold rating while Citi (C) reiterates a Sell rating. The company’s strong app ...